Principal Financial Group’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $18.5K | Buy |
+14,103
| New | +$19.5K | ﹤0.01% | 2150 |
|
|
2025
Q2 | – | Sell |
-12,740
| Closed | -$5.75K | – | 2275 |
|
|
2025
Q1 | $5.75K | Sell |
12,740
-960
| -7% | -$563 | ﹤0.01% | 2167 |
|
|
2024
Q4 | $6.88K | Hold |
13,700
| – | – | ﹤0.01% | 2207 |
|
|
2024
Q3 | $12.4K | Sell |
13,700
-5,577
| -29% | -$5.17K | ﹤0.01% | 2218 |
|
|
2024
Q2 | $19.2K | Buy |
19,277
+1,426
| +8% | +$1.57K | ﹤0.01% | 2342 |
|
|
2024
Q1 | $26.4K | Buy |
17,851
+1,536
| +9% | +$1.74K | ﹤0.01% | 2390 |
|
|
2023
Q4 | $17.8K | Buy |
16,315
+1,080
| +7% | +$1.18K | ﹤0.01% | 2389 |
|
|
2023
Q3 | $18K | Hold |
15,235
| – | – | ﹤0.01% | 2420 |
|
|
2023
Q2 | $21.5K | Buy |
+15,235
| New | +$21.1K | ﹤0.01% | 2407 |
|
|
2022
Q4 | – | Sell |
-14,937
| Closed | -$17K | – | 2502 |
|
|
2022
Q3 | $17K | Sell |
14,937
-26,128
| -64% | -$38.4K | ﹤0.01% | 2463 |
|
|
2022
Q2 | $65K | Sell |
41,065
-4,094
| -9% | -$5.4K | ﹤0.01% | 2441 |
|
|
2022
Q1 | $70K | Sell |
45,159
-33,583
| -43% | -$52.1K | ﹤0.01% | 2464 |
|
|
2021
Q4 | $193K | Sell |
78,742
-45,477
| -37% | -$106K | ﹤0.01% | 2376 |
|
|
2021
Q3 | $313K | Sell |
124,219
-4,548
| -4% | -$11.7K | ﹤0.01% | 2288 |
|
|
2021
Q2 | $367K | Buy |
+128,767
| New | +$333K | ﹤0.01% | 2289 |
|
|
2020
Q2 | – | Sell |
-10,015
| Closed | -$8K | – | 2345 |
|
|
2020
Q1 | $8K | Buy |
+10,015
| New | +$9.97K | ﹤0.01% | 2196 |
|
|
2019
Q4 | – | Sell |
-11,427
| Closed | -$11K | – | 2255 |
|
|
2019
Q3 | $11K | Buy |
+11,427
| New | +$11.8K | ﹤0.01% | 2241 |
|
|
2019
Q2 | – | Sell |
-11,234
| Closed | -$15K | – | 2250 |
|
|
2019
Q1 | $15K | Sell |
11,234
-2,213
| -16% | -$2.75K | ﹤0.01% | 2202 |
|
|
2018
Q4 | $12K | Sell |
13,447
-1,923
| -13% | -$2.95K | ﹤0.01% | 2239 |
|
|
2018
Q3 | $32K | Buy |
15,370
+1,422
| +10% | +$2.99K | ﹤0.01% | 2281 |
|
|
2018
Q2 | $25K | Buy |
13,948
+565
| +4% | +$1.14K | ﹤0.01% | 2267 |
|
|
2018
Q1 | $31K | Buy |
+13,383
| New | +$31.4K | ﹤0.01% | 2194 |
|
|
2017
Q3 | – | Sell |
-13,639
| Closed | -$38K | – | 2226 |
|
|
2017
Q2 | $38K | Sell |
13,639
-2,116
| -13% | -$5.91K | ﹤0.01% | 2244 |
|
|
2017
Q1 | $48K | Buy |
15,755
+1,548
| +11% | +$4.4K | ﹤0.01% | 2185 |
|
|
2016
Q4 | $45K | Buy |
14,207
+1,349
| +10% | +$4.14K | ﹤0.01% | 2204 |
|
|
2016
Q3 | $44K | Hold |
12,858
| – | – | ﹤0.01% | 2146 |
|
|
2016
Q2 | $29K | Buy |
+12,858
| New | +$31.5K | ﹤0.01% | 2151 |
|
|
2015
Q3 | – | Sell |
-17,598
| Closed | -$52K | – | 2203 |
|
|
2015
Q2 | $52K | Buy |
+17,598
| New | +$68.2K | ﹤0.01% | 2168 |
|
|
2014
Q1 | – | Sell |
-23,177
| Closed | -$67K | – | 2289 |
|
|
2013
Q4 | $67K | Buy |
+23,177
| New | +$70K | ﹤0.01% | 2262 |
|
Other funds holding LCTX
BC
DC
RA
Principal Financial Group's LCTX Position: Q2 2026 in Review
Principal Financial Group opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2026: 14,103 shares worth $18.5K. The stake represents ﹤0.01% of the portfolio and ranks #2150 among its holdings. This is a return to the name: Principal Financial Group previously reported a position in LCTX as recently as Q1 2025.
Principal Financial Group first reported a position in LCTX in Q4 2013 and has held it in 29 quarters since. The position peaked at $367K in Q2 2021. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.
- Principal Financial Group held 14,103 shares of Lineage Cell Therapeutics worth $18.5K as of Q2 2026.
- Lineage Cell Therapeutics was a new Principal Financial Group position in Q2 2026.
- Lineage Cell Therapeutics made up ﹤0.01% of Principal Financial Group's portfolio in Q2 2026, its #2150 holding.
- Principal Financial Group first reported a position in Lineage Cell Therapeutics in Q4 2013 and has held it in 29 quarters since.
- Principal Financial Group's Lineage Cell Therapeutics position peaked at $367K in Q2 2021.
- 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.
Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.